Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

H7N9 mutation could reduce vaccine effectiveness - study
H7N9 viruses are currently circulating in poultry populations in China and have so far caused more than 1,600 human cases.
Scientists shed new light on H7N9 viruses in China 

Pirbright scientists have identified a mutation in the H7N9 avian influenza virus that could allow it to escape immune system defences, reducing the effectiveness of vaccines.

H7N9 viruses are currently circulating in poultry populations in China and have so far caused more than 1,600 human cases - over 600 of which have been fatal.

Research published in the Journal of Virology shows that small genetic differences in the virus surface proteins can stop antibodies that protect against a low pathogenic form of the virus from binding to a more virulent form.

This protein, called haemagglutinin, enables the first stage of infection, where the virus attaches to cells and initiates entry into them. Antibodies that bind to the haemagglutinin prevent this process, thereby protecting against infection.

Professor Munir Iqbal, head of the avian influenza group at Pirbright, said: “We discovered that a single amino acid substitution on the H7N9 haemagglutinin, changes its structure enough to reduce antibody binding levels between the two pathotypes.

“This suggests that a single vaccine might not be able to protect against both low and high pathogenicity H7N9 viruses if they carry different amino acid residues at the identified site, stressing the importance of continually monitoring outbreak strains for genetic changes in this region.”

The research team also found that antibodies produced against the high pathogenicity virus showed strong cross-reactivity to both the high and low pathogenicity viruses, compared to those produced against the low pathogenicity virus.

Scientists said this suggests vaccines developed from high pathogenicity strains may be better vaccine candidates for protecting poultry and humans in China. Further research is needed to understand the effect of genetic variations at the site researchers identified in the haemagglutinin.

 

Become a member or log in to add this story to your CPD history

RCVS Knowledge appoints Veterinary Evidence editor-in-chief

News Story 1
 RCVS Knowledge has welcomed Professor Peter Cockcroft as editor-in-chief for Veterinary Evidence.

A world-renowned expert in evidence-based veterinary medicine, Prof Cockcroft will lead the strategic development and editorial quality of the open-access journal. He was previously in the role from 2017-2020.

Katie Mantell, CEO of RCVS Knowledge, said: "We are excited about the extensive knowledge of evidence-based veterinary medicine and clinical veterinary research that Peter brings, and we look forward to working with him over this next phase of the journal's development." 

Click here for more...
News Shorts
Defra to host bluetongue webinar for vets

The Department for Environment, Food and Rural Affairs (Defra) will be hosting a webinar for veterinary professional on bluetongue on Thursday, 25 April 2024.

Topics covered will include the transmission cycle, pathology and pathogenesis, clinical signs (including signs seen in recent BTV-3 cases in the Netherlands), and control and prevention.

The session, which will take place from 6pm to 7.30pm, is part of Defra's 'Plan, Prevent and Protect' webinar series, which are hosted by policy officials, epidemiologists and veterinary professionals from Defra and the Animal and Plant Health Agency. The bluetongue session will also feature insights from experts from The Pirbright Institute.

Those attending will have the opportunity to ask questions. Places on the webinar can be booked online.